Market Newsdesk

Schwab Report: Self-Directed 401(k) Balances Show Steady Growth in Q3; Advised Accounts Reflect Broader Diversification and Higher Account Balances

SAN FRANCISCO–(BUSINESS WIRE)–
According to Charles Schwab’s SDBA Indicators Report, an industry-leading benchmark on retirement plan participant investment activity within self-directed brokerage accounts (SDBAs), the average account balance across all participant accounts finished Q3 2020 at $302,256, a 9% increase year-over-year and a 6% increase from Q2 2020.

SDBAs are brokerage accounts within retirement plans, including 401(k)s and other types of retirement plans, that participants can use to invest retirement savings in individual stocks and bonds, as well as exchange-traded funds, mutual funds and other securities that are not part of their retirement plan’s core investment offerings.

The third quarter SDBA Indicators Report also showed that advised accounts hold higher average account balances compared to non-advised accounts – $473,875 vs $261,240. Participants with advised accounts also have a more diversified asset allocation mix, including a lower concentration of assets in individual securities. For example, the top individual equity holding across all participants is Apple, comprising 13% of equity assets on average. However, advised participants only had approximately 8% of their equity assets in Apple, while non-advised participants had 14%.

Overall, asset allocation remained similar to Q2 with the exception of an increase in equities from 30.15% in Q2 to 32.54% in Q3. The majority of participant assets were held in equities, followed by mutual funds (32%), ETFs (18%), cash (16%), and fixed income (2%).

Allocation Trends

The data also reveals specific asset class and sector holdings within each investment category:

• Mutual funds: Large-cap funds had the largest allocation at approximately 32% of all mutual fund allocations, followed by taxable bond (21%) and international (14%) funds.
• Equities: Information technology remained the largest equity sector holding at 31%, up from 30% in Q2 2020. Apple continues to be the top overall equity holding, comprising 13% of the equity allocation of portfolios. The other equity holdings in the top five include Amazon (6.8%), Tesla (6.1%), Microsoft (3.1%), and Nvidia (1.8%).
• ETFs: Among ETFs, investors allocated the most dollars to U.S. equity (48%), followed by U.S. fixed income (17%), international equity (12%) and sector ETFs (12%).

Other Report Highlights

• On average, participants held 10.8 positions in their SDBAs at the end of Q3 2020, which has remained consistent both year-over-year and quarter-over-quarter. Baby Boomers held more positions in their SDBA than other generations (12.2 vs. Gen X: 10.8, Millennials: 8.3).
• Trading volumes were down slightly quarter-over-quarter at 13.6 average trades per account in Q3 versus 14 in Q2. Participants made the most trades in their equities holdings, followed by ETFs and mutual funds.
• Gen X made up approximately 44% of SDBA participants, followed by Baby Boomers (35%) and Millennials (15%).
• Gen X had the most advised accounts at 46%, followed by Baby Boomers (40%) and Millennials (11%).
• Baby Boomers had the highest SDBA balances at an average of $446,660, followed by Gen X at $250,076 and Millennials at $83,073.

About the SDBA Indicators Report

The SDBA Indicators Report includes data collected from approximately 156,000 retirement plan participants who currently have balances between $5,000 and $10 million in their Schwab Personal Choice Retirement Account^®. Data is extracted quarterly on all accounts that are open as of quarter-end and meet the balance criteria.

The SDBA Indicators Report tracks a wide variety of investment activity and profile information on participants with a Schwab Personal Choice Retirement Account (PCRA), ranging from asset allocation trends and asset flow in various equity, exchange-traded fund and mutual fund categories, to age trends and trading activity. The SDBA Indicators Report provides insight into PCRA users’ perceptions of the markets and the investment decisions they make.

Data contained in this quarterly report is from the third quarter of 2020, and can be found here, along with prior reports.

About Charles Schwab

At Charles Schwab we believe in the power of investing to help individuals create a better tomorrow. We have a history of challenging the status quo in our industry, innovating in ways that benefit investors and the advisors and employers who serve them, and championing our clients’ goals with passion and integrity.

Investors in mutual funds and ETFs should consider carefully information contained in the prospectus, including investment objectives, risks, charges, and expenses. You can request a prospectus by visiting Schwab.com or calling 800-435-4000. Please read the prospectus carefully before investing.

Disclosures:

Brokerage Products: Not FDIC‐Insured • No Bank Guarantee • May Lose Value

The securities shown are for informational purposes only and are not a recommendation to transact in any security.

Through its operating subsidiaries, The Charles Schwab Corporation (NYSE: SCHW) provides a full range of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services to individual investors and independent investment advisors. Its broker-dealer subsidiaries and their affiliates offer a complete range of investment services and products including an extensive selection of mutual funds; financial planning and investment advice; retirement plan and equity compensation plan services; referrals to independent, fee-based investment advisors; and custodial, operational and trading support for independent, fee-based investment advisors through Schwab Advisor Services. Its primary banking subsidiary, Charles Schwab Bank, SSB (member FDIC and an Equal Housing Lender), provides banking and lending services and products. More information is available at www.aboutschwab.com. Follow us on Twitter, Facebook, YouTube and LinkedIn.

This report is for informational purposes only and is not a solicitation, or a recommendation that any particular investor should purchase or sell any particular security.

Schwab Personal Choice Retirement Account^® (PCRA) is offered through Charles Schwab & Co., Inc. (member SIPC), the registered broker/dealer, which also provides other brokerage and custody services to its customers.

All corporate names are for illustrative purposes only and are not a recommendation, offer to sell, or a solicitation of an offer to buy any security.

(1120-OJC7)

View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005239/en/

Mike Peterson

Charles Schwab

330-908-4334

[email protected]

Travis Fishstein

The Neibart Group

718-801-8205

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo

Asana for the Enterprise – Connecting Distributed Teams at Scale

Asana unveils integrations with Atlassian Jira (Server Edition), Microsoft Teams, Slack and Zoom

New Rules automation connects the enterprise’s most essential tools in a click

SAN FRANCISCO–(BUSINESS WIRE)–Asana, Inc. (NYSE: ASAN), a leading work management platform for teams, today announced the addition of new and expanded integrations with Atlassian Jira (Server Edition), Microsoft Teams, Slack and Zoom to its industry-leading app ecosystem featuring nearly 200 integrations. Further enhancing its offerings for enterprise customers, Asana also introduced increased admin capabilities and more ways for teams to work securely with automation, enabling IT teams to effectively deploy and manage their software at scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005371/en/

As 2020 comes to a close, organizations are still struggling to connect and collaborate efficiently, despite having more ways to work asynchronously than ever before. According to an Asana survey conducted in October 2020, enterprise workers switch between an average of 10 apps 25 times per day, resulting in unconnected communication, reduced efficiency and duplication of work.

“Employee experience is the new enabler of customer experience, and the key for enterprises to become more agile in the era of COVID-19 and beyond,” said Alex Hood, Head of Product, Asana. “By empowering their teams with the new tech stack for the enterprise, organizations can move faster and coordinate work effortlessly, no matter where their employees are located.”

Hood continues, “To meet this moment, we’re introducing more ways to connect Asana to the essential apps of the enterprise, including new and enhanced integrations with Zoom, Slack, Microsoft Teams and Atlassian Jira Server Edition, and deepening our own workflow automation and centralized admin control capabilities. As we continue delivering on our vision to be the navigation system for all organizations, we’re proud that Asana is trusted by two-thirds of the Fortune 500, from Cisco to Discovery to McKesson, as their collaborative work management tool of choice.”

Expanding Asana’s App Ecosystem

Zoom for Asana

With the new Zoom for Asana, customers can now attach Zoom call transcripts to Asana tasks for quick reference or to give teammates further context, significantly reducing the number of times teams will have to switch between both platforms. In addition, the recently announced Asana for Zoom Apps will enable Zoom customers to subscribe and receive notifications from Asana projects directly within Zoom chat channels.

“In October, we announced Zoom Apps, enabling customers to use their favorite apps, including Asana, in Zoom for the first time,” said Oded Gal, Chief Product Officer, Zoom. “Today, we’re pleased to partner with Asana on introducing Zoom for Asana, empowering teams to create and link to meetings directly within Asana. By integrating bilaterally across both platforms, Asana and Zoom customers will be able to prioritize their work in one place, driving and simplifying workflows no matter where the work is happening.”

Asana for Slack

With the updated Asana for Slack integration, teams can share milestones, projects and portfolios as unfurls within Slack channels. As one of Asana and Slack’s most popular integrations, the Asana for Slack enhancement builds on the existing ability to create and assign tasks from Slack messages while supporting Slack Enterprise Grid customers for the first time. Enterprise Grid is designed for very large businesses or those in highly regulated industries.

“Slack’s open platform is designed to serve as a critical engagement layer that brings people, processes and systems together in a way that makes work-life simpler,” Steve Wood, VP of Product, Slack Developer Platform. “The latest enhancements to the Asana for Slack integration are emblematic of that vision, delivering expanded collaboration functionality to an even greater set of customers. We look forward to the continued expansion of our work with Asana to build essential tools for the enterprise that will empower our many joint customers to manage work more efficiently.”

Asana for Microsoft Teams

Following the launch of Asana for Microsoft Teams in June 2020, customers can now create tasks directly within Microsoft’s recently launched Teams meetings feature, ensuring that key action items are reflected in Asana in just a few clicks.

“Earlier this year, we expanded our collaboration with Asana with the launch of Asana for Microsoft Teams to empower our customers with the tools they need to securely collaborate, communicate and coordinate their work,” said Mike Ammerlaan, Director of Microsoft 365 Ecosystem Marketing, Microsoft Corp. “We’re continuing to evolve our co-created tools for enterprise companies, including the ability for customers to access Asana via our latest product innovation – Apps in Microsoft Teams meetings.”

Asana for Atlassian Jira (Server Edition)

Coupled with Asana’s current integration for Jira Cloud, Asana for Atlassian Jira (Server Edition) enables teams to create and link Jira issues from directly within Asana tasks, and receive updates on open Jira issues – whether they’re working in the cloud or on-premise.

New Suite of Controls for Enterprise Admins

Asana is also making it easier to protect and manage an organization’s data with new admin controls. Now, enterprise admins have the power to view, block and accept which third-party apps integrate with Asana and control whether users can attach files to tasks. In addition to knowing that data in Asana is encrypted both in transit and at rest for all users and having the ability to terminate user sessions if a device is lost or stolen, enterprise admins can have greater peace of mind that their data is safe and secure, across remote teams and timezones.

“Our marketing and design teams have been using Asana for years, successfully streamlining tasks and processes,” said Alvina Antar, Senior Vice President and Chief Information Officer, Okta. “Given this year’s quick shift to remote work and our long-term strategy around Dynamic Work, we knew it was time to standardize employees onto one platform, and now Okta relies on Asana to organize and orchestrate work. Not only do our employees love Asana, but it also has the capabilities to scale with our rapid growth and improve cross-functional collaboration and productivity — ultimately supporting our transition to Dynamic Work.”

Coming Soon: Integration Automation with Rules

In the coming months, Asana will deliver more ways for teams to create Rules-based automation with essential enterprise integrations, including Teams, Slack and Zoom, to customize and automate work happening across those tools with no coding skills required. For example, a team’s review and approval process in Asana can expand to include external notifications in third party apps, such as Slack and Zoom. As the work progresses in Asana, customizable Rules with integrations will automatically trigger notifications within those platforms to keep teams informed and work moving forward seamlessly.

About Asana

Asana helps teams orchestrate their work, from small projects to strategic initiatives. Headquartered in San Francisco, CA, Asana has more than 82,000 paying organizations and millions of free organizations across 190 countries. Global customers such as Sephora, Sky, Spotify, Viessmann, and Woolworths rely on Asana to manage everything from company objectives to digital transformation to product launches and marketing campaigns. For more information, visit www.asana.com.

Research Methodology

Conducted on behalf of Asana by Sapio Research in October 2020, the survey of 2,353 knowledge workers from companies with more than 5,000 employees included respondents located in Australia, France, Germany, Japan, Singapore, the U.K., and the U.S.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005371/en/

Leah Wiedenmann

[email protected]

415-612-0635

KEYWORDS: Australia/Oceania Australia United States North America California

INDUSTRY KEYWORDS: Data Management Security Technology Mobile/Wireless Software Networks Internet

MEDIA:

Logo

Photo

With the new Zoom for Asana integration, customers can attach Zoom call transcripts to Asana tasks for quick reference or to give teammates further context, significantly reducing the number of times teams will have to switch between both platforms. (Graphic: Business Wire)

Photo

With the expanded Asana for Microsoft Teams integration, customers can now create tasks directly within Microsoft’s recently launched Teams meetings feature, ensuring that key action items are reflected in Asana in just a few clicks. (Graphic: Business Wire)

Photo

Asana for Atlassian Jira (Server Edition) enables teams to create and link Jira issues from directly within Asana tasks, and receive updates on open Jira issues – whether they’re working in the cloud or on-premise. (Graphic: Business Wire)

Photo

With the updated Asana for Slack integration, teams can share milestones, projects and portfolios as unfurls within Slack channels. (Graphic: Business Wire)

Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA

— Priority Review Requested —

SEATTLE–(BUSINESS WIRE)–
Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement, and has received breakthrough therapy designation and orphan drug designation from FDA for HSCT-TMA.

This final portion of the rolling BLA submission, comprised of the BLA’s clinical sections, follows the previously submitted chemistry, manufacturing and controls (CMC) and nonclinical sections, which are under review by FDA. The clinical sections are based on previously reported results of the pivotal trial of narsoplimab in HSCT-TMA in which the drug met its primary endpoint and demonstrated similarly strong response across its secondary endpoints.

Omeros has requested priority review for the BLA, and applicable regulations provide FDA up to 60 days to determine the filing and review designation for the application.

About Omeros Corporation

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a rolling biologics license application under review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. Omeros’ MASP-3 inhibitor OMS906, which targets the complement system’s alternative pathway, recently entered the clinic, and the company’s PDE7 inhibitor OMS527 has successfully completed its Phase 1 trial. Omeros’ pipeline holds a diverse group of preclinical programs including a novel antibody-generating technology and a proprietary GPCR platform through which it controls 54 new GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing small-molecule GPR174 inhibitors. For more information about Omeros and its programs, visit www.omeros.com.

About Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) is a significant and often lethal complication of stem cell transplantation. This condition is a systemic, multifactorial disorder caused by endothelial cell damage induced by conditioning regimens, immunosuppressant therapies, infection, graft-versus-host disease, and other factors associated with stem cell transplantation. Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of HSCT-TMA. The condition occurs in both autologous and allogeneic transplants but is more common in the allogeneic population. In the United States and Europe, approximately 25,000 to 30,000 allogeneic transplants are performed annually. Recent reports in both adult and pediatric allogeneic stem cell transplant populations have found an approximately 40-percent incidence of HSCT-TMA, and high-risk features may be present in up to 80 percent of these patients. In severe cases of HSCT-TMA, mortality can exceed 90 percent and, even in those who survive, long-term renal sequalae (e.g., dialysis) are common. There is no approved therapy or standard of care for HSCT-TMA.

About Narsoplimab

Narsoplimab, also known as “OMS721,” is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2.

A biologics license application (BLA) has been submitted to the U.S. FDA for use of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and the drug is in Phase 3 clinical programs for immunoglobulin A (IgA) nephropathy and atypical hemolytic uremic syndrome (aHUS). The FDA has granted narsoplimab breakthrough therapy designations for HSCT-TMA and for IgA nephropathy; orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies, for the treatment of HSCT-TMA and for the treatment of IgA nephropathy; and fast track designation for the treatment of patients with aHUS. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in HSCT and for treatment of primary IgA nephropathy. For additional information regarding narsoplimab and its clinical trials, visit www.omeros.com/narsoplimab.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely”, “look forward to,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “prospects,” “scheduled,” “should,” “slated,” “targeting,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements, including statements regarding anticipated regulatory submissions, the timing and results of ongoing or anticipated clinical trials, and the therapeutic application of Omeros’ investigational product, are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with product commercialization and commercial operations, unproven preclinical and clinical development activities, the impact of COVID-19 on our business, financial condition and results of operations, regulatory oversight, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 2, 2020, as supplemented by our Quarterly Reports on Form 10-Q filed with the SEC and subsequent filings with the SEC. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005466/en/

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

360.668.3701

[email protected]

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: FDA Health Stem Cells General Health Pharmaceutical Biotechnology

MEDIA:

Logo

CURE Pharmaceutical Issues Letter to Shareholders

OXNARD, Calif.–(BUSINESS WIRE)–CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans.

Highlights of the letter include:

• The Company’s efforts to further position itself as an integrated healthcare company with its recent acquisition of The Sera Labs, a high-margin, multi-channel marketing and branding company with accelerating sales of its more than 20 products in the health & wellness, beauty, and pets categories and strong traction in both e-commerce and wholesale-to-retail distribution with total retail doors exceeding 8,850 in the U.S. to date
  • CURE acquired 100 percent of privately held The Sera Labs for $20 million, which consists primarily of stock with key earn out considerations totaling up to an additional $20 million within two years of completing the acquisition.
  • The Sera Labs Founder and CEO Nancy Duitch, who is well-known for her track record for launching some of the largest-selling products on the market, will help the Company generate revenue on its existing technologies in a wellness vertical, without the need for partners and further strengthen the already sales-generating SeraLabs® brand.
• The Sera Labs newest consumer product that uses CURE’s patented and advanced oral thin film strip technology under the trademark name Nutri-Strips with RAD3 (Rapid Activation Delivery) to deliver novel vitamins and supplements to consumers across the nation.
  • Formulations include a sleep aid called Sleep A.S.A.P.™, EnergY™ designed to enhance performance and mental focus, an electrolyte and muscle recovery product called RecoverB™, and immunD™ for immune support.
• CURE earning NSF International, cGMP certification for its 25,000 square foot manufacturing facility
  • This certification enables manufacturers to become independently certified by NSF as complying with cGMP requirements as listed in Section 8 of NSF/ANSI Standard 173. This certification positions CURE’s manufacturing capabilities at the forefront of quality standards set by the various regulatory agencies.
• The Company’s recent pharmacokinetic (PK) study on its 25mg cannabidiol (CBD) oral thin film (OTF) showing improved bioavailability of cannabidiol in healthy subjects
  • In 14 healthy adults, those who used the OTF experienced a significantly higher serum concentration (Cmax) and significantly faster absorption (Tmax) than those who consumed a commercially available CBD soft gel. The study also suggests that the CUREform™ delivery platform, which entails solubilization and encapsulation of the molecule, might deliver better results than solubilization alone, as used in the soft gel product, and may play a synergistic or additive role in bioavailability.
• The Company’s future plans and focus on research and development into CURE’s pharmaceutical programs and The Sera Labs commitment to innovating its offerings with a “tele-wellness” program and exciting new products.

The Company’s Chief Executive Officer Rob Davidson commented, “2020 has not been without its challenges for any industry; however, CURE is still well-positioned to become a fully-integrated health and wellness company, as propelled by the acquisition of SeraLabs. We continue to forge ahead in our pharmaceutical research using our proven drug delivery platforms and adapt to service the burgeoning nutraceutical market. We’ve focused on improving our manufacturing capabilities and proved yet again the superiority of our drug delivery technology. All in all, I am more confident than ever in CURE’s ability to capitalize on our vision of delivering the promise of healthier lives.”

To read the Letter to Shareholders in full, please visit the company’s website HERE. You can download the letter HERE.

About SeraLabs

SeraLabs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD. SeraLabs® creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names SeraRelief™, SeraTopical™, SeraLabs™, Gordon’s Herbals™ and SeraPets™. SeraLabs® sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness, and pet care, SeraLabs® products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: www.SeraLabsHealth.com and follow @theseralabs, @nutristrips or contact: [email protected]

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.

As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

Forward Looking Statement

Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005454/en/

Media Contact:

Monica M. Jaramillo

LABEL the Agency,

Los Angeles,

[email protected],

424.273.8675

Investment Media Contact:

Kathryn Brown

Account Supervisor

CMW Media

[email protected]

858-264-6600

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Cosmetics Retail Manufacturing Marketing Pharmaceutical Communications Other Consumer General Health Online Retail Discount/Variety Other Retail Supermarket Other Manufacturing Veterinary Consumer Health

MEDIA:

Posted on November 18, 2020 9:03 am

Cigniti Technologies is now a proud Underwriter of PhillyCIO

 Cigniti Technologies is now a proud Underwriter of PhillyCIO

PHILADELPHIA–(BUSINESS WIRE)–
Cigniti Technologies, a global leader in independent quality engineering and software testing services, is now a strategic Underwriter of PhillyCIO, a local arm of the InspireCIO Leadership Network. Together, they regularly convene leading CIOs, foster meaningful relationships and help CIOs thrive in today’s most challenging C-suite executive role.

As an Underwriter of PhillyCIO , Cigniti would be part of InspireCIO programs such as CIO Philadelphia Advisory Board Meetings, PhillyCIO Awards Nominee Event, PhillyCIO Awards Finalist Event, CIO Only Programs, CIO Wine Experience, and Philadelphia CIO of the Year ORBIE Awards and for the promotions purposes by leveraging the key resources to support the expansion.

Speaking on this association, Kalyan Rao Konda, President at Cigniti Technologies, said, “We are excited to be part of this association which brings together the CIOs across industries of Philadelphia. This association would help understand from the CIOs themselves the innovation and technology trends. This platform provides an opportunity for Cigniti to share the latest innovation and best practices related to Quality Engineering.”

Jen Wise, Executive Director of PhillyCIO, said, “We are thrilled to have Cigniti joining PhillyCIO as an Underwriter of the chapter. As an Underwriter, Cigniti will play an essential role in helping to connect local CIOs with their peers through year-round, non-commercial chapter programs and recognizing deserving Philadelphia-based CIOs through the annual PhillyCIO of the Year ORBIE Awards. Cigniti’s support of these programs provides ongoing opportunities to foster relationships among top CIOs. We look forward to working together to serve and celebrate the PhillyCIO community.”

InspireCIO programs are made possible through the corporate support of strategic partners known as Underwriters. These organizations represent the highest-level investors in local chapters and the senior executives of Underwriter organizations are regarded as peers by the CIOs serving on Advisory board of Philadelphia.

About Cigniti:

Cigniti Technologies is a Global Leader in Independent Quality Engineering & Software Testing services. Cigniti’s 2,500+ experienced professionals are spread across US, Canada, UK, Australia, India, UAE, and South Africa. We are a strategic quality engineering partner for leading global organizations and assist them in accelerating time-to-market by predicting and preventing unanticipated failures, leveraging AI-driven, proprietary Continuous Testing & Test Automation solutions, with customer-centricity at the core of the transformation. Our test offerings are Quality Engineering, Advisory & Transformation, Digital Assurance, and Quality Assurance solutions.

About PhillyCIO

PhillyCIO is the preeminent peer leadership network for Philadelphia chief information officers. PhillyCIO membership is comprised exclusively of CIOs (or equivalent executive roles) from public and private companies, government, education, healthcare and non-profit organizations.

PhillyCIO is led by a CIO Advisory Board which sets the annual program agenda for the association. Events are facilitated by a full-time Executive Director and professional staff. PhillyCIO events are CIO-led and attended solely by CIO-level executives.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005650/en/

Midhun Pingili, [email protected]

KEYWORDS: Pennsylvania United States India North America Asia Pacific

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Internet

MEDIA:

Logo

A Distinguished U.S. University Medical Center Extends Vital Security Program Partnership

Expanded partnership highlights CynergisTek’s growth of its cybersecurity managed service client base

AUSTIN, Texas–(BUSINESS WIRE)–CynergisTek, (NYSE AMERICAN: CTEK), a leading cybersecurity firm helping more than 1,000 healthcare facilities navigate emerging security and privacy issues, today announced a nearly $1 million managed services contract extension of its strategic partnership with a leading university medical center which will fund crucial expanded services for the healthcare institution at a time when research organizations are in dire need of vital protection from cyber adversaries.

The expanded program includes CynergisTek’s new security validation service, which provides confirmation that processes, technology, and security controls are responding effectively to simulated attacks. By doing so, clients can develop and evaluate defensive strategies and demonstrate a solid ROI from their security investment when healthcare organizations everywhere are facing new obstacles and dynamic threats.

A recent CynergisTek report stated that organizations that have invested in security-focused resources show year-over-year improvement in their NIST CSF scores. Leveraging CynergisTek’s managed services program, allows organizations with the foundation to implement successful strategic plans and can continue enhancing their security and privacy programs while maintaining a predictable year over year budget.

“Clients who aim to expand their managed services to include security validation are not just evaluating their security posture, they are taking the steps to actually validate its effectiveness in production,” said Caleb Barlow, CEO and president of CynergisTek. “Moving from traditional ‘assessments’ to ‘security validation’ is not only innovative but it sets a new bar for other leading institutions to follow.”

About CynergisTek, Inc.

CynergisTek is a top-ranked cybersecurity firm dedicated to serving the information assurance needs of the healthcare industry. CynergisTek offers specialized services and solutions to help organizations achieve privacy, security, and compliance goals. Since 2004, the company has served as a partner to hundreds of healthcare organizations and is dedicated to supporting and educating the industry by contributing to relevant industry associations. The company has been recognized by KLAS as a top performing firm in healthcare cybersecurity and was recognized as being the top Cybersecurity Consultants for Assessment, Audit, Strategy and Implementation in healthcare by Black Book Market Research.

Forward-Looking Statements

This release contains certain forward-looking statements relating to the business of CynergisTek that can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “may” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product/service development, long and uncertain sales cycles, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, future capital requirements, competition from other providers, the ability of our vendors to continue supplying the company with equipment, parts, supplies and services at comparable terms and prices and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. CynergisTek is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005666/en/

Investor Relations Contact:

CynergisTek, Inc.

Paul Anthony

[email protected]

Media Contact:

Allison+Partners

Jaime Tero

415-755-8639

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Data Management Health Security Technology Hospitals Managed Care Software

MEDIA:

Logo